Neurodegeneration
How safe is clinic lecanemab in practice?
Open access · cc by · source: Europe PMC
Among 234 memory-clinic patients on lecanemab, infusion reactions (37%) and ARIA (22%) were common but generally manageable; mild dementia had much higher symptomatic ARIA.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Brain multi-omics reveals multimodal AD molecular profiles including a severe cluster.
Integrating transcriptomic/proteomic/metabolomic/lipidomic brain data yielded four multimodal profiles, including Knight-C4 with pronounced dysregulation and worse clinical features.
Scope note — clinic anti-amyloid treatment experience — not a multi-omics subtype discovery
Limits the claim's scope: a different population, assay, or outcome.
Specialty clinics are delivering lecanemab with real-world workflow constraints.
A specialty memory-clinic report on lecanemab treatment adds practice-level evidence beside biomarker/pathology marker papers.
Evidence for the claim as stated.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on Alzheimer’s and MCI markers
Integrating transcriptomic/proteomic/metabolomic/lipidomic brain data yielded four multimodal profiles, including Knight-C4 with pronounced dysregulation and worse clinical features.
Placed as supporting evidence on Alzheimer’s and MCI markers
A specialty memory-clinic report on lecanemab treatment adds practice-level evidence beside biomarker/pathology marker papers.
Placed as a scope qualifier on Alzheimer’s and MCI markers
Integrating transcriptomic/proteomic/metabolomic/lipidomic brain data yielded four multimodal profiles, including Knight-C4 with pronounced dysregulation and worse clinical features.
Placed as supporting evidence on Alzheimer’s and MCI markers
A specialty memory-clinic report on lecanemab treatment adds practice-level evidence beside biomarker/pathology marker papers.
Study at a glance
- Design
- Cohort — Retrospective consecutive case series of specialty-clinic lecanemab initiations
- N
- N=234 · Patients with early symptomatic AD receiving ≥1 infusion
- Population
- Early symptomatic Alzheimer disease patients at Washington University Memory Diagnostic Center
- Outcome
- Infusion reactions, ARIA (including symptomatic), and treatment withdrawal
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
How safe is clinic lecanemab in practice?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
234 patients initiated lecanemab; mean age 74.4 years.
The 234 patients treated with lecanemab had a mean age of 74.4 (SD, 6.7) years, 117 were female (50%), and 117 were male (50%).
Infusion-related reactions occurred in 37%.
Infusion-related reactions occurred in 87 patients (37%) and were typically mild.
Key findings
IRR 37%; ARIA 22% (ARIA-E 15%, isolated ARIA-H 6.7%); symptomatic ARIA 5.7% overall but 27% in mild dementia vs 1.8% in MCI/very mild; 9.8% withdrew (4.3% for ARIA); no macrohemorrhage/death.
Methodology
Reviewed consecutive lecanemab starts (Aug 2023–Oct 2024), dosing every 2 weeks, MRI monitoring, and adverse events through Dec 2024.
Limitations
Long-term efficacy vs placebo in this clinic sample, or risk under every eligibility exception.
Related papers in this topic
Same topic cluster — not a recommendation engine.
- How tau buildup shapes brain networks in dementia
- How does brain structure change in early Parkinson's disease?
- How does brain inflammation affect connectivity and thinking in AD?
- Can a new PET imaging tracer distinguish different tau diseases?
- Does brain region loss predict memory decline in Parkinson's?